Romain Ragonnet1, Jennifer A Flegg2, Samuel L Brilleman1,3, Edine W Tiemersma4, Yayehirad A Melsew1, Emma S McBryde1,5, James M Trauer1,6. 1. School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. 2. School of Mathematics and Statistics, University of Melbourne, Melbourne, Victoria, Australia. 3. Victorian Centre for Biostatistics, Melbourne, Victoria, Australia. 4. KNCV Tuberculosis Foundation, South Holland, The Hague, The Netherlands. 5. Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Queensland, Australia. 6. Victorian Tuberculosis Program at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Abstract
BACKGROUND: Tuberculosis (TB) natural history remains poorly characterized, and new investigations are impossible as it would be unethical to follow up TB patients without treatment. METHODS: We considered the reports identified in a previous systematic review of studies from the prechemotherapy era, and extracted detailed data on mortality over time. We used a Bayesian framework to estimate the rates of TB-induced mortality and self-cure. A hierarchical model was employed to allow estimates to vary by cohort. Inference was performed separately for smear-positive TB (SP-TB) and smear-negative TB (SN-TB). RESULTS: We included 41 cohorts of SP-TB patients and 19 cohorts of pulmonary SN-TB patients in the analysis. The median estimates of the TB-specific mortality rates were 0.389 year-1 (95% credible interval [CrI], .335-.449) and 0.025 year-1 (95% CrI, .017-.035) for SP-TB and SN-TB patients, respectively. The estimates for self-recovery rates were 0.231 year-1 (95% CrI, .177-.288) and 0.130 year-1 (95% CrI, .073-.209) for SP-TB and SN-TB patients, respectively. These rates correspond to average durations of untreated TB of 1.57 years (95% CrI, 1.37-1.81) and 5.35 years (95% CrI, 3.42-8.23) for SP-TB and SN-TB, respectively, when assuming a non-TB-related mortality rate of 0.014 year-1 (ie, a 70-year life expectancy). CONCLUSIONS: TB-specific mortality rates are around 15 times higher for SP-TB than for SN-TB patients. This difference was underestimated dramatically in previous TB modeling studies, raising concerns about the accuracy of the associated predictions. Despite being less infectious, SN-TB may be responsible for equivalent numbers of secondary infections as SP-TB due to its much longer duration.
BACKGROUND:Tuberculosis (TB) natural history remains poorly characterized, and new investigations are impossible as it would be unethical to follow up TB patients without treatment. METHODS: We considered the reports identified in a previous systematic review of studies from the prechemotherapy era, and extracted detailed data on mortality over time. We used a Bayesian framework to estimate the rates of TB-induced mortality and self-cure. A hierarchical model was employed to allow estimates to vary by cohort. Inference was performed separately for smear-positive TB (SP-TB) and smear-negative TB (SN-TB). RESULTS: We included 41 cohorts of SP-TBpatients and 19 cohorts of pulmonary SN-TBpatients in the analysis. The median estimates of the TB-specific mortality rates were 0.389 year-1 (95% credible interval [CrI], .335-.449) and 0.025 year-1 (95% CrI, .017-.035) for SP-TB and SN-TBpatients, respectively. The estimates for self-recovery rates were 0.231 year-1 (95% CrI, .177-.288) and 0.130 year-1 (95% CrI, .073-.209) for SP-TB and SN-TBpatients, respectively. These rates correspond to average durations of untreated TB of 1.57 years (95% CrI, 1.37-1.81) and 5.35 years (95% CrI, 3.42-8.23) for SP-TB and SN-TB, respectively, when assuming a non-TB-related mortality rate of 0.014 year-1 (ie, a 70-year life expectancy). CONCLUSIONS: TB-specific mortality rates are around 15 times higher for SP-TB than for SN-TBpatients. This difference was underestimated dramatically in previous TB modeling studies, raising concerns about the accuracy of the associated predictions. Despite being less infectious, SN-TB may be responsible for equivalent numbers of secondary infections as SP-TB due to its much longer duration.
Authors: Malancha Karmakar; Romain Ragonnet; David B Ascher; James M Trauer; Justin T Denholm Journal: BMC Infect Dis Date: 2022-01-24 Impact factor: 3.090
Authors: Sourya Shrestha; Emily A Kendall; Rebekah Chang; Roy Joseph; Parastu Kasaie; Laura Gillini; Anthony Todd Fojo; Michael Campbell; Nimalan Arinaminpathy; David W Dowdy Journal: BMC Med Date: 2021-10-14 Impact factor: 11.150
Authors: Chu-Chang Ku; Peter MacPherson; McEwen Khundi; Rebecca H Nzawa Soko; Helena R A Feasey; Marriott Nliwasa; Katherine C Horton; Elizabeth L Corbett; Peter J Dodd Journal: BMC Med Date: 2021-11-10 Impact factor: 8.775
Authors: Cristina Curreli; Valentina Di Salvatore; Giulia Russo; Francesco Pappalardo; Marco Viceconti Journal: Ann Biomed Eng Date: 2022-09-17 Impact factor: 4.219
Authors: Romain Ragonnet; Bridget M Williams; Angela Largen; Joaquin Nasa; Tom Jack; Mailynn K Langinlur; Eunyoung Ko; Kalpeshsinh Rahevar; Tauhid Islam; Justin T Denholm; Ben J Marais; Guy B Marks; Emma S McBryde; James M Trauer Journal: Int J Epidemiol Date: 2022-10-13 Impact factor: 9.685